J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK250.00.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Vosser is a 2-star analyst with an average return of 0.5% and a 45.23% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and Sanofi.

In addition to J.P. Morgan, Novo Nordisk also received a Hold from Deutsche Bank ‘s Emmanuel Papadakis in a report issued on March 26. However, on March 19, Bernstein initiated coverage with a Sell rating on Novo Nordisk (LSE: 0QIU).

Based on Novo Nordisk’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of DKK79.14 billion and a net profit of DKK26.89 billion. In comparison, last year the company earned a revenue of DKK85.68 billion and had a net profit of DKK28.23 billion

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.